Furthermore, traditional neuroendocrine tumor markers like chromogranin A and other novel biomarkers should also be included in a future confirmatory study and thus could potentially increase the diagnostic sensitivity in combination with cfDNA integrity and hypomethylation. This evidence concerns the gene CHGA and neuroendocrine neoplasm.